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Abstract
Objectives and Design: We determined in a rat model (1) the presence and dynamics of alloantibodies recognizing MHC
complexes on quiescent Brown-Norway (BN) splenic cells in the sera of Lewis (LEW) recipients of Brown-Norway iliolumbar
vein grafts under tacrolimus immunosuppression; and (2) the presence of immunoglobulins in the wall of acute rejected
vein allografts.
Materials and Methods: Flow cytometry was used for the analysis of day 0, 14 and 30 sera obtained from Lewis recipients of
isogeneic iliolumbar vein grafts (group A) or Brown-Norway grafts (group B, C) for the presence of donor specific anti-MHC
class I and II antibodies. Tacrolimus 0.2 mg/kg daily was administered from day 1 to day 30 (group C). Histology was
performed on day 30.
Results: Sera obtained preoperatively and on day 30 were compared in all groups. The statistically significant decrease of
anti MHC class I and II antibody binding was observed only in allogenic non-immunosuppressed group B (splenocytes: MHC
class I - day 0 (93%67% ) vs day 30 (66%67%), p= 0.02, MHC class II - day 0 (105%63% ) vs day 30 (83%65%), p= 0.003; B-
cells: MHC class I - day 0 (83%65%) vs day 30 (55%66%), p= 0.003, MHC class II - day 0 (101%61%) vs day 30 (79%66%),
p= 0.006; T-cells: MHC class I - day 0 (71%67%) vs day 30 (49%65%), p= 0.04). No free clusters of immunoglobulin G
deposition were detected in any experimental group.
Conclusion: Arterialized venous allografts induce strong donor-specific anti-MHC class I and anti-MHC class II antibody
production with subsequent immune-mediated destruction of these allografts with no evidence of immunoglobulin G
deposition. Low-dose tacrolimus suppress the donor-specific antibody production.
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Introduction
There remain a group of vascular patients with critical leg
ischemia who are not suitable for the use of greater saphenous vein
or prosthetic grafts in peripheral vascular reconstruction. In
specific indications, allogeneic veins are used in these patients.[1]
However, allogeneic veins are immunogenic because of the
expression of both class I and class II major histocompatibility
complex (MHC) antigens on their wall cells.[2] These antigens
stimulate immune responses in the host that lead to the destruction
of the allovenous wall structure. The rejection is represented by
graft thrombosis or by graft dilatation with the risk for graft
rupture.[3,4]
One possibility for increasing the patency rates of venous
allografts is the use of immunosuppressive drugs.[5] However,
immunosuppression is not routinely used in clinical practice.[1]
When immunosuppression is used, cyclosporine A is the most
frequently administered drug to patients with allovenous bypass-
es.[6–8].
However, recently published data confirmed considerable
vascular side effects from cyclosporine A.[9,10] Contrary to
cyclosporine A, tacrolimus, a newer and more potent immuno-
suppressive drug routinely used in renal and liver transplant
patients, showed significantly advantageous characteristics related
to hypertension, dyslipidaemia, and renal function in transplant
patients.[9] Moreover, tacrolimus seems to be a promising
compound in a new generation of coronary drug eluting
stents.[11].
In our previous experiments, we used the rat ileolumbar vein to
abdominal aorta transplantation model to study the effect of low-
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dose tacrolimus immunosuppression on rejection changes and
adaptation of venous allografts to arterialisation in rats. Tacroli-
mus inhibited cell-mediated rejection, and the immunosuppressed
alloveins developed characteristic signs of the wall remodelling
process observed in syngeneic arterialised veins.[12].
However, the significance of antibody-mediated rejection in
chronic vascular rejection and consecutive failure of transplanted
organs seems to be more and more important.[13] Moreover, the
production of donor-specific antibodies against the major histo-
compatibility complex (anti-MHC) in dogs was clearly connected
with venous allografts thrombosis.[4].
In the present study, we determined the following parameters:
(1) the presence and dynamics of alloantibodies recognizing MHC
complexes on Brown-Norway (BN) splenocytes, quiescent BN
splenic B-cells and T-cells in the sera of Lewis (LEW) recipients of
BN iliolumbar vein grafts under low dose tacrolimus immunosup-
pression; and (2) the presence of immunoglobulin in the rejected
allovein wall. For this purpose, we screened for the presence of
donor-specific anti-MHC class I and II antibodies in recipient’s
sera that was obtained previously in our Brown-Norway to Lewis
rat model of allovenous arterialisation.[12].
Materials and Methods
Ethics statement
The principles of laboratory animal care were followed and all
rats were maintained according to the National Institute of Health
Guidelines. Ethical approval by a local ethical committee of the
Institute for Clinical and Experimental Medicine was obtained for
this study.
Animals
Adult male inbred Brown-Norway (BN; RT1n) and Lewis
(LEW; RT1l) rats were obtained from Charles River (Sulzfeld,
Germany). Male LEW rats (N=23, 200–340 g) were used as
recipients of allogeneic or syngeneic iliolumbar vein grafts. Male
BN rats (N= 9, 220–300 g) were used as donors of allogeneic
iliolumbar vein grafts. Male LEW rats (N= 3, 280–300 g) were
used as donors of syngeneic iliolumbar vein grafts. Each
transplanted animal was housed in a separate cage during the
entire 30-day follow-up period. Only animals that survived the
whole follow-up period were included in this study.
Operative procedure
Iliolumbar vein transplantation into the abdominal aorta was
described in detail in our previous publication.[12] Briefly, donor
animals were anaesthetised with an intramuscular injection of
ketamine 100 mg/kg (Narkamon, Spofa a.s., Prague, Czech
Republic) and xylazine 10 mg/kg (Rometar, Spofa a.s., Prague,
Czech Republic). Two segments of the iliolumbar veins (1–1.5 cm
in length) were excised and stored in saline solution at room
temperature until transplantation. The median ischemic time for
the vein allografts was 160 min.
The recipient animals with planned follow-up were anaesthe-
tised with less invasive anaesthesia (intramuscular injection of
20 mg/kg sufentanil (Sufenta, Janssen Pharmaceutica Inc., Beerse,
Belgium) and 1 mg/kg azaperone (Stresnil, Janssen Pharmaceu-
ticals Inc., Beerse, Belgium) to ensure a more natural awakening.
The venous allografts were implanted into the infrarenal aorta
of the recipient rats after a midline laparotomy using a running
10/0 monofilament suture (Ethicon Inc., Sommerville, New
Jersey, USA).
Neither anticoagulants nor anti-platelet drugs were used in the
experiment.
Animal groups
The recipient animals were divided into three groups. Animals
in group A received isogeneic venous transplantation (LEW to
LEW, N=4), and animals in group B received allogeneic venous
transplantation (BN to LEW, N=9). Neither group received
immunosuppressive therapy. Animals in group C received
allogeneic venous transplantation (BN to LEW, N=7) and were
immunosuppressed with daily intramuscular injections of low-dose
tacrolimus (0.2 mg/kg daily).
Immunosuppressive therapy
The immunosuppressive protocol of allogeneic group C animals
was the same as described previously.[12] Briefly, tacrolimus
(Prograf, Astellas Pharma Inc., Tokyo, Japan) was suspended in
saline solution and administered intramuscularly in daily doses of
0.2 mg/kg. Immunosuppression was initiated on day 1 after
transplantation and was administered for the entire 30-day follow-
up period. On day 30, tacrolimus blood levels were evaluated
using an enzyme-enhanced immunoassay technique (Emit 2000
Tacrolimus assay, Dade Behring Inc., Deerfield, Illinois, USA),
and the venous grafts were removed after a midline re-laparotomy
and processed for histology and immunohistochemistry (see
below). The animals were then euthanized by intracaval admin-
istration of a lethal dose of thiopental (Thiopental, Spofa a.s.,
Prague, Czech Rep).
Blood samples
Blood samples were collected in all groups on days 0, 14, and 30
by orbital sinus puncture as described by van Herck.[14]
Splenocytes
Spleens from other male BN rats (N= 10, weight 200–250 g,
Charles River, Sulzfeld, Germany) were used as a source of
splenocytes for this study. The spleens were removed after midline
laparotomy in anesthetized animals (intramuscular anaesthesia
with sufentanil and stresnil as described above). The animals were
then killed with intracaval administration of a lethal dose of
thiopental (Thiopental, Spofa, Czech Republic). The spleens were
removed and immediately processed according to a protocol for
splenocyte preparation used in our laboratory. Briefly, the excised
spleen was minced into small pieces, pressed through a strainer
using the plunger end of a syringe, and washed with phosphate
buffered saline solution (PBS). The cell suspension was placed on
Biocoll separating solution (BioScience, Nottingham, UK) and
centrifuged at 2000 rpm for 20 minutes. The supernatant was
resuspended in 10% foetal calf serum (FCS) with RPMI 1640
(Sigma-Aldrich Chemie GmbH, Buchs SG, Switzerland) and
centrifuged at 1200 rpm for 10 minutes. This step was done twice.
A cell count and viability check using trypan blue was performed
afterwards. Cells were then stored in tubes with freezing medium
(Iscove’s Modified Dulbecco’s Medium + 20% FCS) in liquid
nitrogen until processing.
Flow cytometry analysis
In vitro binding of sera obtained in all three animal groups and
quiescent BN splenocytes was determined by flow cytometry as
described previously.[15] Briefly, cells were thawed, washed in
phosphate-buffered saline (PBS), and resuspended in PBS solution
with 1% foetal bovine serum (FBS). One hundred thousand cells
were incubated for 30 min at 4uC with 10 ml of rat serum. Cells
were washed twice in PBS (1% FBS) then incubated with original
antibodies as follows: MHC expression on quiescent BN spleno-
cytes was determined using a Biotin-MHC class I (anti-RT1.Ac,
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OX-27, Acris Antibodies GmbH, Herford, Germany) or a Biotin-
MHC class II (anti-RT1.D, OX-17, BD Biosciences, Heidelberg,
Germany) primary antibody and a PE-Cy7-streptavidin secondary
antibody (BD Biosciences, Heidelberg, Germany). Furthermore,
spleen cells were incubated with PE-CD3 (anti-CD3, G 4.18, BD
Biosciences, Heidelberg, Germany) and stained with FITC-
CD45RA antibody (anti-CD45, OX 33, BD Biosciences, Heidel-
berg, Germany) to distinguish between T- and B-cells. Ten
thousand cells were acquired on a FACSCanto II flow cytometer
(BD Biosciences, Heidelberg, Germany) and analysed using
FACSDiva software (BD Biosciences, Heidelberg, Germany).
Graphic presentations as histograms allowed the determination
of mean fluorescence intensity on a log scale.
MHC class I or class II antibody binding of the cells without
previous serum incubation was set to 100%.
Detection of immunoglobulins in the venous wall
Immunohistochemical analysis of transplanted iliolumbar veins
was performed according to methods described previously.[12]
Briefly, after removal the veins were embedded in Sakura Finetek
Tissue Tek Cryomold holders (Sakura Finetek, Tokyo, Japan) and
Sakura Finetek Tissue Tek O.C.T. compound (Sakura Finetek,
Tokyo, Japan). The samples were frozen in 2-methylbutane (Fluka
Chemika, Buchs, Switzerland), cooled with liquid nitrogen, and
stored until processed at 280uC. After processing, the 8-mm thick
sections were rinsed in PBS and air-dried. The tissues were then
incubated with an antibody directly conjugated with fluorescein
isothiocyanate (Chemicon International Inc, Temecula, Califor-
nia, USA) for 30 min. The specimens were then dipped in
glycerine medium and immediately analysed under a fluorescence
microscope.
Statistical analysis
Values are expressed as the mean 6 standard error measure-
ment (SEM). Comparisons between two groups were made using
Student’s t-test. Values of p,0.05 were considered statistically
significant.
Results
The results of the transplantation, histology, immunohisto-
chemistry, and cell-mediated rejection of iliolumbar vein grafts
were presented in detail previously.[12] Immunosuppressive
therapy with tacrolimus was necessary for the adaptation of the
venous allograft to arterialisation in the previous study.[12]
In the present study, we determined the following parameters:
(1) the presence and dynamics of alloantibodies recognizing MHC
complexes on quiescent BN splenic B-cells and T-cells in the sera
of LEW recipients of BN iliolumbar vein grafts using different
fluorescence-labelled antibodies; and (2) the presence of immuno-
globulin in the venous wall. The serum antibodies from allografted
LEW rats, where presented, were competitive binding to MHC
class I and MHC class II molecules on splenocytes and quiescent
splenic BN B-cells and T-cells. The inhibition of the fluorescence-
labelled MHC class I and II antibody binding consequently
decreased the measured fluorescence signal.
MHC class I positive splenic cells
Blood samples were collected preoperatively (day 0) and on day
14 and 30 after transplantation. Syngeneic group A sera showed
no inhibition of the fluorescence-labeled MHC class I antibody
binding to BN-splenocyte during the entire follow-up period.
(Fig. 1A).
By contrast, sera from allogeneic non-immunosuppressed group
B animals obtained on day 30 after transplantation significantly
decreased the binding of fluorescence-labeled MHC class I
antibody to BN spleen cells (66%67%), compared with day 0
sera (93%67%, p=0.02).
In addition, sera from the allogeneic non-immunosuppressed
group B obtained on day 14 and day 30 showed significant
inhibition of fluorescence-labelled MHC class I antibody binding
to BN spleen cells (73%68%; 66%67%), compared with day 14
and day 30 sera from the syngeneic group A (104%68%, p=0.03;
104%65%, p=0.002).
Allogeneic immunosuppressed group C sera obtained on day 30
showed no significant inhibition of fluorescence-labeled MHC
class I antibody binding (79%66%) compared with day 0 sera
(96%6 7%). Compared to group A sera (104%65%) showed
group C day 30 sera significant inhibition (79%66%, p=0.02).
MHC class II positive splenic cells
Syngeneic group A sera as well as allogeneic immunosuppressed
group C sera showed no significant inhibition of the fluorescence-
labeled MHC class II antibody binding to BN spleen cells during
the entire follow-up period (Fig.1B ).
By contrast, day 30 sera from the allogeneic non-immunosup-
pressed group B rats showed significant inhibition of fluorescence-
labelled MHC class II antibody binding to BN spleen cells
(83%65%) compared with group B day 0 sera (105%63%,
p=0.003) and day 14 sera (112%62%, p=0.002) as well as day 30
sera from the syngeneic group A (108%65%, p=0.006).
MHC class I positive splenic B-cells
Quiescent BN splenic B-cells were identified as CD45RA-
positive cells.
Syngeneic group A sera as well as allogeneic immunosuppressed
group C sera showed no significant inhibition of fluorescence-
labelled MHC class I antibody binding to BN B-cells during the
entire follow-up period (Fig. 2A).
By contrast, sera from allogeneic non-immunosuppressed group
B obtained on day 14 and day 30 showed inhibition of
fluorescence-labelled MHC class I antibody binding. This binding
was significantly decreased in the presence of day 30 sera
(55%66%) compared with day 0 sera (83%65%, p=0.003).
In addition, sera from the allogeneic non-immunosuppressed
group B obtained on day 14 and day 30 showed significant
inhibition of fluorescence-labelled MHC class I antibody binding
to splenic B-cells (69%66%; 55%66%) compared with day 14
and day 30 sera from the syngeneic group A (91%61%, p=0.007;
86%63%, p=0.00007) as well as the day 14 and day 30 sera from
allogeneic group C (89%65%, p=0.02; 93%64% p=0.0002).
MHC class II positive splenic B-cells
Quiescent BN splenic B-cells were identified as CD45RA-
positive cells.
Sera from the syngeneic group A and allogeneic immunosup-
pressed group C showed no significant inhibition of fluorescence-
labelled MHC class II antibody binding to BN B-cells during the
entire follow-up period (Fig. 2B).
By contrast, day 30 sera from the allogeneic non-immunosup-
pressed group B rats showed significant inhibition of fluorescence-
labelled MHC class II antibody binding to B-cells (79%66%)
compared with day 0 (101%61%, p=0.006) and day 14
(104%61%. p=0.002) sera.
Antibody-Mediated Rejection of Venous Allografts
PLOS ONE | www.plosone.org 3 March 2014 | Volume 9 | Issue 3 | e91212
MHC class I positive T-cells
Quiescent BN splenic T-cells were identified as CD3-positive
cells.
No significant inhibition of the fluorescence-labelled MHC class
I antibody binding to BN T-cells was observed in sera from
syngeneic group A or allogeneic immunosuppressed group C
during the entire follow-up period (Fig. 3A).
By contrast, day 30 sera from allogeneic non-immunosup-
pressed group B showed significant inhibition of fluorescence-
labelled MHC class I antibody binding to T-cells (49%65%)
compared with day 0 sera (71%67%, p=0.04). Additionally, the
inhibition observed was significantly stronger compared with
syngeneic group A day 30 (76%64%, p=0.005) and allogeneic
immunosuppressed group C day 30 (76%67%, p=0.02) sera.
MHC class II positive T-cells
Quiescent BN splenic T-cells were identified as CD3-positive
cells. However, these quiescent splenic T-cells do not express
MHC class II antigens. We did not observe any significant
inhibition of fluorescence-labelled MHC class II antibody binding
in the presence of sera obtained from any of the three
experimental groups during the entire follow-up period (Fig. 3B).
Immunoglobulins in the venous wall
Immunofluorescent staining showed no free clusters of IgG
deposition on day 30 after arterialisation of both immunosup-
pressed and non-immunosuppressed iliolumbar alloveins. (Fig.4,
Fig. 5) IgG positive fluorescent spots were observed only in the
wall of rejected non-immunosuppressed allovenous graft. The area
of fluorescence positivity correlated with cellular infiltration of
immunocompetent cells.
Discussion
The results of our experimental study of antibody production
after allovenous arterialisation showed massive induction of donor-
specific anti-MHC class I and class II antibody production by
recipients of allogeneic veins. The allogeneic venous allografts in
non immunosuppressed rats did not develop signs of venous wall
adaptation to arterialisation. The venous wall, including smooth
muscle cells (SMC), was destroyed by a massive infiltration of
immunocompetent cells of recipient origin. The SMC were unable
to proliferate and adapt to the new biomechanical conditions.
However, donor-specific class I and class II antibody production
and the destruction of venous allografts were suppressed by low-
dose tacrolimus immunosuppression.
The importance of anti-MHC antibody production during the
process of rejection of the venous allografts was experimentally
documented. Antibody production after histo-incompatible fem-
Figure 1. Dynamic of anti splenic cells MHC class I and II antibodies concentrations. The percentage binding of the fluorescence-labelled
MHC class I (A) and MHC class II (B) antibody to BN splenic cells in the presence of sera from group A, B, or C obtained on day 0, 14, or 30 after
transplantation. Sera from the allogeneic non-immunosuppressed group B, taken on day 30, significantly inhibited fluorescence-labelled MHC class I
and MHC class II antibody binding to splenic cells, compared to day 0 sera. Error bars represent SEM, *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0091212.g001
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oral vein to femoral artery interposition in dogs appeared
specifically at 4 weeks, and lasted until graft occlusion was
detected, between postoperative weeks 4 and 12.[4] Furthermore,
85% of studied animals developed antibodies that activated the
complement system and lysed the donor endothelial cells.[16]
Inhibiting antibody production in 75% of animals using a
combination of cyclosporine A at a dosage of 10 mg/kg per day
with mycophenolate mofetil at a dosage of 20 mg/kg per day was
observed in animals with a 100% patency rate at 20 weeks. Given
alone, neither cyclosporine A nor mycophenolate mofetil im-
proved the overall patency rate of venous allografts, and did not
suppress the development of donor-specific antibodies.[16]
The same research group observed the deposition of IgG
isotype antibodies in the walls of arterialised venous allografts in
dogs 4 to 12 weeks after thrombosis developed.[4] However, the
authors were unable to distinguish between real IgG deposition
and deposits related to B cell infiltration, as moderate infiltration
of mononuclear cells and mild infiltration of plasma cells were
observed within the media and adventitia of allografts with
thrombosis. In our model, we observed activation of donor-specific
anti-MHC class I and class II production during the first 2 weeks
after arterialisation. This production was sufficiently suppressed by
low-dose tacrolimus immunosuppression, with mean tacrolimus
blood levels of 5.6 ng/ml. However, we did not observe any IgG
deposition in the walls of rejected venous allografts. The IgG
positivity was observed probably only in cell membranes of
invading recipient MHC class II positive cells. This is in contrast
with the direct involvement of IgG deposition in the destructive
process we observed previously in the rejection of non-immuno-
suppressed arterial allografts.[17] This is probably owing to a
greater content of smooth muscle cells and MHC antigens in the
arterial wall compared with veins.
The exact role of anti MHC antibodies in the process of venous
rejection is not clear. [4] This phenomenon was studied mainly in
the process of alloarterial rejection. Thaunat et al. reported in BN
to LEW aortic transplant model that anti–MHC I alloantibodies
play a key role in the arterial remodeling during the graft
rejection.[18,19] They demonstrated that the binding of anti–
MHC class I alloantibodies to the SMCs of the medial donor
exerts a sequential biphasic effect. First, they induce a transient
production of growth factors that promote an inappropriate
response to injury of the intima. These growth factors act in a
paracrine fashion to promote the proliferation of SMCs of the
recipient that may contribute to the development of an obstructive
neointima. In a second phase, the binding of anti–MHC I
alloantibodies drives the apoptosis of SMCs of the donor, resulting
in the shrinkage of the media.
The importance of anti-MHC antibody production after vessel
transplantation in humans was confirmed as well. Strong anti-
MHC class I and class II antibody production was observed in the
Figure 2. Dynamic of anti splenic B-cells MHC class I and II antibodies concentrations. The percentage binding of the fluorescence-
labelled MHC class I (A) and MHC class II (B) antibody to BN splenic B-cells, identified as CD45RA-positive cells, in the presence of sera from group A,
B, or C obtained on day 0, 14, or 30 after transplantation. Only sera from the allogeneic non-immunosuppressed group B, taken on day 14 or day 30,
significantly inhibited fluorescence-labelled MHC class I and MHC class II antibody binding to splenic B-cells. Error bars represent SEM, *p,0.05,
**p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0091212.g002
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sera of non-immunosuppressed end-stage renal disease patients
with an allovenous haemodialysis access.[20] Moreover, the
donor-specific anti-MHC class I and class II antibody response
was also seen after valved allograft implantation in children with
congenital heart disease.[21] This immune-mediated response has
the potential for deleterious effects on valved allograft function and
persists late after surgery [22] The immunosuppressive therapy
with mycophenolic mofetil[21] but not azatioprine [23] reduced
this HLA antibody response.
Based on previous reports,[24] cyclosporine A is the immuno-
suppressant most frequently used by vascular surgeons after
venous and arterial allograft implantation over the past 20
years.[6,25,26] Balzer et al. were interested in determining the
prevalence and specificity of anti-MHC antibodies in vascular
patients after peripheral reconstruction with venous allografts.[8]
They found a high rate of donor-specific allosensitisation, which
included not only a humoral response against constitutively
expressed class I antigens, but also extended to class II antigens.
This was probably due to upregulation of MHC class II molecules
by endothelial cells and SMC in the field of the inflammatory
reaction caused by vessel injury, thrombosis, or stasis in the grafted
vessels. In this study, all patients received low-dose cyclosporine A
immunosuppression with serum levels of 50–90 ng/ml.
Randon et al. reviewed data from patients after cryopre-
served vein allograft implantations followed by 1 year long
Figure 3. Dynamic of anti splenic T-cells MHC class I and II antibodies concentrations. The percentage binding of the fluorescence-
labelled MHC class I (A) and MHC class II (B) antibody to BN splenic T-cells, identified as CD3-positive cells, in the presence of sera from group A, B, or
C obtained on day 0, 14, or 30 after transplantation. Only sera from the allogeneic non-immunosuppressed group B obtained on day 14 or day 30
showed significant inhibition of fluorescence-labelled MHC class I antibody binding to splenic T-cells. Error bars represent SEM, *p,0.05, **p,0.01,
***p,0.001.
doi:10.1371/journal.pone.0091212.g003
Figure 4. Histological features of rejected non-immunosup-
pressed alloveins. Representative light microscopic photograph
showing the histological features of alloveins in non-immunosup-
pressed rats (group B) 30 days following transplantation into the
infrarenal abdominal aorta: A - vein stained for immunoglobulins with a
fluorescein isothiocyanate-conjugated antibody (Chemicon Internation-
al Inc, Temecula, California, USA). No free clusters of immunoglobulins
were detected in the allovenous wall. B - vein stained for CD4+ cells
with anti-CD4 antibody (OX-8, Cymbus Biotechnology LTD, South-
ampton, UK) as described previously.[12] Massive infiltration of CD4+
immunocompetent cells (stained brown) led to the destruction of
allovenous wall with no histological signs of arterialisation. Original
magnification6100.
doi:10.1371/journal.pone.0091212.g004
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immunosuppressive therapy consisting of cyclosporine A resulting
in blood levels of 100 to 150 mg/dL.[6] They concluded that this
method led to increased limb salvage and patency rates compared
with those described for prosthetic grafts at the infra-popliteal level
in most studies. However, no determination of antibody produc-
tion was performed in these patients.
Mirelli et al. used in 33% of patients after fresh and
cryopreserved arterial allografts replacement due to prosthetic
graft infection cyclosporine treatment with blood levels between
100 and 200 ng/ml.[25] Despite this treatment, donor-specific
anti-MHC class I and class II production was detected. However,
antibody production in the cyclosporine A group was less
pronounced and was delayed compared with non-immunosup-
pressed patients.
However, recently published data confirm considerable vascular
side effects with use of cyclosporine A.[9,10] Clinical studies in
transplanted patients show that cyclosporine A treatment results in
endothelial dysfunction, an important risk factor for cardiovascular
adverse events. Moreover, cyclosporine A increased treatments for
anti-hypertension and lipid-lowering in these patients [9].
The immunosuppressant tacrolimus and cyclosporine A belong
to the group of calcineurin inhibitors. However, tacrolimus is more
potent and less toxic compared with cyclosporine A.[27]
Experimental arterial transplantation model proved that tacroli-
mus 0.2 mg/kg is sufficient for survival of endothelial cells of
donor origin in arterial allografts; however, cessation of the use of
tacrolimus resulted in severe destruction of the arterial wall.[28]
The influence of tacrolimus on antibody production was not
studied.
Tacrolimus 0.2 mg/kg used in our experiment was established
in accordance with the effective dose used in other arterial
experiments.[28] This dose led to blood concentrations of 5 ng/
ml. Moreover, we confirmed that this low blood concentration
inhibits intimal hyperplasia in arterialised syngeneic veins in our
previous study,[29] and inhibited histological signs of allogeneic
vein rejection [12].
Conclusions
In conclusion, our data confirm the strong immunogenicity of
venous allografts that involve both cell- and antibody-mediated
immune responses during the rejection processes of these grafts. In
our model, we observed cell-mediated rejection of allografted
illiolumbar veins and donor-specific anti-MHC class I and class II
antibody production only in non-immunosuppressed allogeneic
animals. Signs of cell-mediated rejection were confirmed by
massive infiltration and destruction of the venous wall by MHC
class II-positive, CD4+, and CD8+ cells of host origin.[12]
Moreover, we observed increased donor-specific anti-MHC class I
and class II antibody concentrations in the graft recipients sera on
days 14 and 30 after transplantation. All these processes were
suppressed by low-dose tacrolimus immunosuppression. However,
the possible beneficial effect of tacrolimus immunosuppression in
vessel allograft implantation in vascular patients need to be
confirmed in a clinical study.
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